Alopecia Areata Study Reveals Sharp Racial Divides in Immune Disease Risk

Alopecia areata has long been understood as a disease of the immune system, one in which the body’s own defenses turn against the hair follicles and produce patches of nonscarring hair loss that can range from a few small bald spots to complete loss of hair on the scalp and body. Dermatologists have also known for years that patients with alopecia areata are more likely than the general population to develop other immune-mediated conditions, from thyroid disease to lupus. What has been far less clear is whether that risk looks the same across racial groups. A new retrospective cohort study published in the Archives of Dermatological Research suggests that it does not, and the differences it documents are striking enough to change how clinicians think about screening and monitoring patients with this condition.

The research, led by Nicole J. Baker of Sidney Kimmel Medical College at Thomas Jefferson University and the University of Pennsylvania, together with Simona A. Alomary of Rutgers New Jersey Medical School and senior authors Temitayo Ogunleye and Susan Taylor of the University of Pennsylvania’s Department of Dermatology, set out to fill a conspicuous gap in the literature. Although previous work, including a 2025 systematic review and meta-analysis of immune-mediated disorders in alopecia areata patients, had established that these comorbidities cluster together, few studies had examined how endocrine, gastrointestinal, and dermatologic immune conditions distribute differently between Black and white patients. Given that the prevalence of many autoimmune diseases is known to vary by race in the United States, the authors argued that a race-stratified analysis was overdue.

To answer the question, the team turned to TrinetX, a large U.S. collaborative network of de-identified electronic health record data. The design was a retrospective cohort study, meaning the investigators looked backward at existing patient records to compare disease frequencies between groups defined by alopecia areata status and race. The primary analysis compared Black patients with alopecia areata, a cohort of 3,887 individuals, against white patients with the condition, who numbered 14,407. This head-to-head comparison between the two racial groups with the same diagnosis formed the core of the study and allowed the researchers to isolate differences in associated immune-mediated disorders within the alopecia areata population itself.

The secondary analyses added an important layer of context. Rather than comparing only the two alopecia areata cohorts to each other, the researchers also compared Black patients with the condition to Black controls with no prior history of alopecia areata, and white patients with the condition to white controls. This race-matched design matters because baseline rates of immune disease differ substantially between racial groups in the general population. A condition that appears common among white alopecia areata patients might simply reflect high prevalence among white Americans generally, rather than a specific link to alopecia areata. By anchoring each racial cohort to its own race-matched control group, the study could distinguish between disease associations that track with alopecia areata itself and those that reflect broader population patterns.

The results of the primary comparison revealed a pattern of differences that the authors describe as significant across several organ systems. Black patients with alopecia areata showed markedly higher relative risks than their white counterparts for several conditions. The largest gap appeared for systemic lupus erythematosus, a multisystem autoimmune disease, which was associated at a relative risk of 2.58 in Black patients compared with white patients with alopecia areata. Hyperthyroidism, the overactive form of thyroid dysfunction, showed a relative risk of 1.84. Atopic disease also diverged: atopic dermatitis carried a relative risk of 1.42, allergic rhinitis 1.44, and asthma 1.32, all elevated in Black patients relative to white patients with the same hair loss diagnosis.

The direction of association reversed for a different set of conditions. Black patients with alopecia areata had substantially lower frequencies of several immune-mediated disorders compared with white patients. Hypothyroidism, the underactive thyroid state that is the more common thyroid abnormality in many populations, showed a relative risk of just 0.25. Celiac disease, an immune-mediated enteropathy triggered by gluten, registered at 0.23, and psoriasis, the chronic immune-mediated skin disease, at 0.29. Crohn’s disease, the inflammatory bowel condition, was associated at a relative risk of 0.5. Only rheumatoid arthritis showed no significant difference between the two racial groups, standing out as the one major immune-mediated condition in the analysis that appeared to distribute evenly across the alopecia areata population regardless of race.

The secondary, race-matched comparisons delivered a finding that is in some ways the most clinically consequential of all. When Black patients with alopecia areata were compared to Black controls, and white patients with the condition to white controls, the association with immune-mediated disorders was increased for every outcome examined. In other words, regardless of race, having alopecia areata signals a heightened likelihood of carrying at least one additional immune-mediated condition when measured against peers of the same racial background. This confirms, in a race-stratified framework, the broader principle that alopecia areata rarely travels alone and that the immune dysregulation underlying it extends beyond the hair follicle.

From a technical standpoint, the use of relative risk as the primary effect measure is worth unpacking. Relative risk expresses the ratio of disease frequency in one group to disease frequency in another, so a relative risk of 2.58 for lupus means the condition was roughly two and a half times as frequent among Black alopecia areata patients as among white ones in this dataset. Conversely, a relative risk of 0.23 for celiac disease means the condition was less than a quarter as frequent in the Black cohort. The authors are careful to note, however, that these ratios must be interpreted alongside the underlying prevalence of each disorder by race in the general population. A large relative risk for a rare condition may translate into fewer absolute cases than a modest relative risk for a common one, and baseline racial differences in disease prevalence can shape both the magnitude and the direction of the observed ratios.

The study’s methodology also reflects the practical realities and limitations of large-scale health record research. Because the analysis relied on de-identified data from the TrinetX network, the requirement for individual informed consent was waived, and the work was conducted in accordance with the ethical principles of the Declaration of Helsinki. Retrospective claims and record-based designs of this kind can reveal associations across very large populations, but they capture diagnosed disease, which depends on access to care and diagnostic patterns that themselves vary by race. The authors nonetheless argue that the consistency and magnitude of the differences they observed warrant attention, and the findings align with a growing body of evidence, including prior analyses of racial and ethnic differences in autoimmune disease prevalence in U.S. claims and electronic health record data, showing that autoimmune risk is not distributed uniformly across the American population.

What the study ultimately delivers is a practical message for clinicians and a research agenda for scientists. For dermatologists and primary care physicians evaluating a patient with alopecia areata, the results suggest that race should inform the differential diagnosis of associated immune conditions: a Black patient with alopecia areata deserves particular vigilance for lupus, hyperthyroidism, and atopic disease, while a white patient warrants closer attention to hypothyroidism, celiac disease, psoriasis, and Crohn’s disease. At the same time, the universal elevation of immune-mediated disease risk relative to race-matched controls reinforces that every alopecia areata patient, whatever their background, merits ongoing awareness of comorbid autoimmunity. For researchers, the findings raise mechanistic questions about why the same follicular autoimmune process appears to travel with different systemic companions in different populations, a puzzle that likely involves genetics, environment, and immune regulation in combinations that large cohort studies are only beginning to untangle.

Subject of Research: Racial differences in immune-mediated comorbidities among patients with alopecia areata

Article Title: Differences in risk of immune-mediated disorders among black and white patients with alopecia areata: a retrospective cohort study

Article References: Baker, N. J., Alomary, S. A., Ogunleye, T., & Taylor, S. (2026). Differences in risk of immune-mediated disorders among black and white patients with alopecia areata: a retrospective cohort study. Archives of Dermatological Research, 318(1), Article 419. https://doi.org/10.1007/s00403-026-04891-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04891-2

Keywords: alopecia areata, autoimmune disease, systemic lupus erythematosus, atopic dermatitis, thyroid disease, psoriasis, celiac disease, Crohn's disease, rheumatoid arthritis, racial health disparities, retrospective cohort study, dermatology